Gilead, Allergan, Novo and Valeant chiefs make the list of world's top 10

Gilead CEO John Martin

Pharma CEOs are doing a pretty good job at the helm--at least where the Harvard Business Review is concerned. Four of them--Gilead Sciences' ($GILD) John Martin, Allergan's ($AGN) David Pyott, Novo Nordisk's ($NVO) Lars Rebien Sorensen and Valeant Pharmaceuticals' ($VRX) J. Michael Pearson--made the publication's top 10, ranked by their market cap growth and shareholder returns. More

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.